Navigation Links
C-myc required by the immune system

c-myc, a gene commonly involved in cancer onset, has been found to have a role in the immune system's normal function according to a study published today in Blood. The surprising finding, by a Swiss research team led by investigators from the Lausanne Branch of the international Ludwig Institute for Cancer Research (LICR), showed that c-myc functions in the immune system's 'memory' of previous infections.

In order to rapidly and efficiently respond to new infections, the immune system evolved such that it stores a 'memory' of previous attack by pathogens. The specialized cells involved in this process are known as 'T memory cells'. The T memory cells are normally maintained at a low level that can be rapidly expanded if the pathogen is detected again. The maintenance of normal, low levels, or 'homeostasis', of T memory cells is dependent on a signalling factor, a so-called cytokine, known as 'IL- 15.

"Very little is known about the signalling pathways that actually control IL-15-dependent homeostasis," explains LICR's Dr. H. Robson MacDonald, the senior author of the study. "By analyzing genetically engineered mouse models with reduced c-myc, reduced IL-15 or absent IL-15, we discovered that it's actually c-myc, which is known primarily as an oncogene, that acts downstream of the IL-15 signaling pathway to regulate T memory cell homeostasis."

According to Dr. MacDonald, the study is basic research that may have implications for therapies of the future. "Understanding how immune memory works might allow us to improve therapeutic vaccines against, say, malaria or cancer. The unexpected finding is that this study is also a cautionary tale. Before we design new therapies that inactivate a gene product, which is an approach being considered for c-myc in cancer, we need to be very sure that we are not going to be also destroying a vital role in a normal process such as the body's immune system."


'"/>

Source:Ludwig Institute for Cancer Research


Page: 1

Related biology news :

1. Gene variations explain drug dose required to control seizures
2. B cells are required for development of epithelial cancer associated with chronic inflammation
3. Malignant melanoma cells secrete protein required for embryo formation
4. New study reveals signaling pathways required for expansion of pancreas stem cells
5. Fox Chase Cancer Center scientists identify immune-system mutation
6. Genetically modified natural killer immune cells attack, kill leukemia cells
7. Studies reveal methods viruses use to sidestep immune system
8. Jumping gene helps explain immune systems abilities
9. Scientists solve structure of key protein in innate immune response
10. Rats infected as newborns grew up vulnerable to memory problems during an immune challenge
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017 According to a report ... derivatives market is fragmented due to the presence of a large pool ... Thermo Fisher , and Sigma-Aldrich, compete with each other in ... collectively, held more than 76% of this market in 2016.  ... As of now, a ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? ... partnerships and joint development activities. , “Dr. Floyd’s career has spanned 30 years ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
Breaking Biology Technology: